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Abstract
Background: Development of noninvasive molecular assays to improve disease diagnosis and patient monitoring is a
critical need. In renal transplantation, acute rejection (AR) increases the risk for chronic graft injury and failure. Noninvasive
diagnostic assays to improve current late and nonspecific diagnosis of rejection are needed. We sought to develop a test
using a simple blood gene expression assay to detect patients at high risk for AR.
Methods and Findings: We developed a novel correlation-based algorithm by step-wise analysis of gene expression data in
558 blood samples from 436 renal transplant patients collected across eight transplant centers in the US, Mexico, and Spain
between 5 February 2005 and 15 December 2012 in the Assessment of Acute Rejection in Renal Transplantation (AART)
study. Gene expression was assessed by quantitative real-time PCR (QPCR) in one center. A 17-gene set—the Kidney Solid
Organ Response Test (kSORT)—was selected in 143 samples for AR classification using discriminant analysis (area under the
receiver operating characteristic curve [AUC] = 0.94; 95% CI 0.91–0.98), validated in 124 independent samples (AUC= 0.95;
95% CI 0.88–1.0) and evaluated for AR prediction in 191 serial samples, where it predicted AR up to 3 mo prior to detection
by the current gold standard (biopsy). A novel reference-based algorithm (using 13 12-gene models) was developed in 100
independent samples to provide a numerical AR risk score, to classify patients as high risk versus low risk for AR. kSORT was
able to detect AR in blood independent of age, time post-transplantation, and sample source without additional data
normalization; AUC= 0.93 (95% CI 0.86–0.99). Further validation of kSORT is planned in prospective clinical observational
and interventional trials.
Conclusions: The kSORT blood QPCR assay is a noninvasive tool to detect high risk of AR of renal transplants.
Please see later in the article for the Editors’ Summary.
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Introduction
Despite the application of high-throughput discovery methods
for improved detection of disease-specific biomarkers [1–4], there
is ambiguity about the path to developing a clinically applicable
molecular assay with sufficiently high sensitivity and specificity,
such that it can be used in practice for disease diagnosis and
patient care management. In kidney transplantation, acute
rejection (AR) occurs in about 15%–20% of patients using the
current standard of care for immunosuppression and is detected by
an invasive biopsy following a drift in the patient’s serum
creatinine, the current peripheral marker for graft injury.
However, a drift in serum creatinine is nonspecific for AR and
occurs only after substantive graft damage. In addition, in a
number of patients, AR occurs subclinically, without a drift in
serum creatinine [5], and thus these AR cases remain largely
undetected until extensive graft damage develops [6]. Both AR
and subclinical AR represent major risk factors for developing
chronic graft injury and graft loss, which not only require cost-
intensive patient care (with dialysis costs of up to US$100,000/
year per person in the US) but also reduce the quality of life of
patients. Some transplant programs perform protocol biopsies as a
means of frequent graft monitoring, but thereby increase the risk
of unnecessary invasive procedures in patients who do not have
AR, and add to the financial burden of insurance payers.
Furthermore, biopsy histology is subject to sampling error [7,8]
and is not predictive of AR. The development of a sensitive,
specific, and noninvasive test for the risk of AR is therefore a
critical and currently unmet need in transplantation. In the present
study we developed a simple blood quantitative real-time PCR
(QPCR) test called the Kidney Solid Organ Response Test
(kSORT) to predict AR, improve risk stratification assessment in
transplantation, and provide relevant information for immuno-
suppression decision-making [9,10].
Methods
Ethics Statement
All patients gave written informed consent to participate in the
study, and the study was approved by the individual institutional
review boards at Stanford University, California Pacific Medical
Center, Emory University, University of Pittsburgh Medical
Center, University of California Los Angeles, University of
California San Francisco, Bellvitge University Hospital, and the
Hospital Infantil de Me´xico Federico Go´mez. All procedures were
conducted according to the principles expressed in the Declaration
of Helsinki [11].
Study Design
The Assessment of Acute Rejection in Renal Transplantation
(AART) study was designed in a collaborative effort in eight renal
transplant centers in the United States, Mexico, and Spain, and
utilized 558 peripheral blood (PB) samples from 436 adult and
pediatric renal transplant patients for developing a simple blood
QPCR test for AR diagnosis and prediction in recipients of diverse
ages, on diverse immunosuppression, and subject to transplant-
center-specific protocols. Patients ,20 y of age were included in
the pediatric cohort, and patients $20 y were included in the
adult cohort. The mean age in the pediatric dataset was
13.20 y64.76 y, and the mean age in the adult dataset was
47.43 y614.59 y. Blood samples were collected from transplant
recipients cross-sectionally during clinical follow-up visits and were
matched with a contemporaneous kidney allograft biopsy between
2005 and 2012. Centers that participated in the AART study were
Stanford University, Stanford, California (Stanford; n=162
pediatric samples); Hospital Infantil de Me´xico Federico Go´mez
Laboratorio de Investigacion en Nefrologia, Mexico City, Mexico
(Mex; n=23 pediatric samples); Emory University, Atlanta,
Georgia (Emory; n=43 adult samples); University of California
Los Angeles, Los Angeles, California (UCLA; n=105 adult
samples); University of Pittsburgh, Pittsburgh, Pennsylvania
(UPMC, n=132 adult samples); California Pacific Medical
Center, San Francisco, California (CPMC; n=37 adult samples);
University of California San Francisco, San Francisco, California
(UCSF; n=40 adult samples); and Bellvitge University Hospital,
Barcelona, Spain (Barcelona; n=16 samples). Samples were split
into a training set of 143 AR and No-AR adult samples collected
in non-clinical-trial settings in four centers (AART143 cohort) for
gene selection and model training; a first validation set of 124
independent AR and No-AR adult ($20 y) and pediatric (,20 y)
samples (AART124 cohort) collected by each participating center,
for validation of selected genes for AR detection across ages,
centers, and settings; and a second prospective validation set of
191 adult and pediatric samples serially collected up to 6 mo prior
to and after a rejection biopsy (AART191 cohort) for evaluation of
AR prediction. Blood samples from these three cohorts were
simultaneously measured on the microfluidic high-throughput
BioMark QPCR platform (Fluidigm, South San Francisco, CA)
[12] for a total of 43 genes. The final kSORT assay of 17 genes for
noninvasive detection of AR was locked in a third validation set of
100 adult and pediatric samples (AART100 cohort) on the Applied
Biosystems (ABI; Foster City, CA) QPCR platform with the
development of a novel algorithm (kSORT analysis suite [kSAS]).
21 patients in the AART143 cohort contributed samples to the
AART100 cohort (Figure 1; Tables 1 and S2). Histology readings
of the matched biopsies were not assessed in a centralized manner.
Patient and Sample Information
All adult patients included in this study were enrolled in the
regular transplant program at each center. Pediatric patients were
those participating in an investigator-initiated clinical trial [13]
who also gave written informed consent to participate in this study.
Patients did not undergo additional study-specific procedures, and
no adverse events were reported. Each PB sample analyzed in this
study was paired with a contemporaneous renal allograft biopsy
(within 48 h) from the same patient, in all cases of AR (n=188)
and all cases of No-AR (n=370), with the exception of 12 samples
collected before or after a rejection and 13 samples from clinically
stable patients (stable defined as absence of a drift in serum
creatinine .20% of baseline, no donor-specific antibodies [DSA]
and no rejection within 3 mo post-transplantation). Blood samples
collected at the time of clinically indicated biopsies (drift in serum
creatinine .20% of baseline) were included in the analyses if
obtained prior to any immunosuppression treatment intensifica-
tion. Blood samples collected at the point of protocol biopsies were
obtained from all pediatric patients at engraftment; at 3, 6, 12 and
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24 mo post-transplantation; and additionally at the times of
clinically suspected graft dysfunction [2]. In the adult cohort the
majority of patients had clinically indicated biopsies only for
allograft dysfunction; protocol biopsies in the adult cohort were
obtained from patients enrolled in Barcelona (n=16) at 6 mo
post-transplantation. Multiple PB–biopsy pairs from the same
patient were utilized as long as each biopsy had a conclusive
phenotypic diagnosis. Each biopsy was scored by the center
pathologist at each enrolling clinical site using the latest Banff
classification criteria for renal allograft pathology [14]. The blood–
biopsy pairs were categorized as AR (n=188) or No-AR (n=370).
AR included both cellular and humoral types and was defined as
presence of (1) acute interstitial and tubular Banff scores $1 or (2)
lesions in the glomeruli and peritubular capillary compartments
paired with diffuse positive C4d staining at peritubular capillaries
(humoral AR). No-AR was defined as an absence of any
histological evidence of AR. In the No-AR group, there were 40
samples that either met the Banff criteria for chronic allograft
injury (samples displaying interstitial fibrosis/tubular atrophy
scores $1; n=3) or exhibited chronic calcineurin inhibitor
(CNI) toxicity (n=6), BK polyomavirus (BKV) infection (n=4),
or other graft injury such as acute tubular nephritis (n=27). While
19 cases met the criteria of humoral rejection, the remaining AR
biopsies were considered cell-mediated rejection or mixed
rejection if they had absent C4d staining but detectable DSA.
Samples included in the AART study were collected between 5
February 2005 and 15 December 2012.
Sample Collection and Processing
Blood was collected in 2.5-ml PAXgene Blood RNA Tubes
(PreAnalytiX, Qiagen, Valencia, CA), in Ficoll tubes for PB
lymphocyte (PBL) isolation, or in heparin-coated tubes for PB
mononuclear cell (PBMC) isolation. Total RNA was extracted
using the column-based method kits of PreAnalytiX (Qiagen) for
PAXgene tubes and RNeasy (Qiagen) for PBLs and PBMCs as per
manufacturer’s protocol. Total RNA was measured for RNA
integrity using the RNA 6000 Nano LabChip Kit on a 2100
Bioanalyzer (both from Agilent Technologies, Santa Clara, CA),
with suitable RNA defined by an RNA integrity number
exceeding 7 [15,16].
Quantitative Polymerase Chain Reaction
cDNA synthesis. cDNA synthesis was performed using
250 ng of extracted quality mRNA from the PB samples using
the SuperScript II first strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA) as per the manufacturer’s protocol.
Total RNA sample preparation for microfluidic
QPCR. Samples were prepared for microfluidic QPCR analysis
of 43 genes by taking 1.52 ng of total RNA from cDNA synthesis
and processing it through specific target amplification and sample
dilution as described by Fluidigm using pooled individual ABI
Taqman assays for each gene, excluding ribosomal 18S RNA.
Briefly, specific target amplification was performed using 1.52 ng
of cDNA with the pooled Taqman assays in multiplex with
Taqman PreAmp Master Mix (ABI) to 5 ml of final volume, for 18
cycles in a Vapo-Protect thermal cycler (Eppendorf, Hamburg,
Germany), then diluted 1:5 with sterile water (Gibco, Invitrogen,
Carlsbad, CA).
Microfluidic QPCR. Microfluidic QPCR was performed on
the 96.96 dynamic array (Fluidigm) using 2.25 ml of the diluted
cDNA sample from the specific target amplification, along with
Taqman assays for each gene, Taqman Universal Master Mix,
and Fluidigm loading reagent as outlined in the manufacturer’s
protocol, by priming and loading the chip via the HX IFC
Controller (Fluidigm) and performing the QPCR in the BioMark
QPCR platform (Fluidigm), with default parameters for gene
expression data collection as advised by Fluidigm.
ABI QPCR. Standard protocols were used for QPCR
reactions on the ABI 7900 Sequence Detection System or the
ViiA7 (ABI) under standard conditions (10 min at 95uC, 40 cycles
Figure 1. AART study design in 436 unique adult/pediatric renal transplant patients from eight transplant centers. 558 PB samples
from 436 adult and pediatric renal transplant patients collected from eight independent transplantation centers in the US, Spain, and Mexico were
assessed. Emory, UCLA, UPMC, CPMC, UCSF, and Barcelona contributed adult samples, Mexico and Stanford, pediatric samples. For kSORT QPCR
analysis, cross-sectional AART samples were divided into three cohorts: AART143, n=143 adult samples from 135 patients for kSORT gene modeling;
AART124, n= 124 independent adult (n=59) and pediatric (n=65) samples from 107 adult (n= 52) and pediatric (n=55) patients (for independent
kSORT validation); AART100, n= 100 adult (n= 78) and pediatric (n=22) samples from 96 adult (n=75, of which 21 patients were also included in
AART143) and pediatric (n= 21) patients for final kSORT assay lock and clinical translation. For kSORT QPCR analyses, longitudinal samples were
included in AART191: n= 191 adult (n= 94) and pediatric (n= 97) serial samples from 98 adult (n= 58) and pediatric (n=40) patients for kSORT
prediction. Detailed demographic patient information is shown in Table 1; detailed sample and patient flow is outlined in Table S2.
doi:10.1371/journal.pmed.1001759.g001
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of 15 s at 95uC, 30 s at 60uC), using the same TaqMan gene
expression assays (ABI) utilized in the Fluidigm QPCR.
Statistical Analysis
QPCR data preprocessing and normalization. The rela-
tive amount of mRNA expression in each sample was calculated
using the comparative threshold cycle (CT) method [12].
Expression values for all genes were normalized to ribosomal
18S RNA (18S) as 18S showed the least variability in gene
expression across all samples when compared to the expression of
three additional housekeeping genes tested (GAPDH, B2M,
ACTB). Visualization of the raw QPCR data and identification
of external confounders were done in Partek Genomics Suite
version 6.6 (Partek, St. Louis, MO) by unsupervised principal
component analysis, hierarchical clustering, and analysis of
covariance, and in R by the Empirical Bayes method, which uses
estimations for the least squares parameters (mean and variance)
for each gene (ComBat method using the SVA package in R) [17].
RNA source (PBMCs, PBLs, or PAXGene), blood sample
collection (non-standardized non-clinical-trial versus standardized
clinical trial collection protocols), and patient age group (pediatric
or adult) were significantly associated with differential gene
expression between AR and No-AR groups by analysis of variance
(ANOVA) (p,0.05) and were thus included as random categorical
factors in the batch removal feature (mixed effect model ANOVA)
provided in Partek Genomics Suite for additional data normali-
zation applied to the Fluidigm QPCR data, where factors were
chosen at random to correct for an overall variability associated
with these factors [18] (Figure S1).
Selection of 43 genes for AR screening. The 43-rejection-
gene set represents a combination of significant genes in acute
renal allograft rejection identified by whole genome microarray
analysis of biopsy and paired blood samples transcriptionally
profiled from patients with and without biopsy-confirmed AR.
The discovery process for these genes has been previously
published by us [2,19]. Ten of the 43 rejection genes (CFLAR,
DUSP1, IFNGR1, ITGAX, MAPK9, NAMPT, NKTR, PSEN1,
RNF130, RYBP) were significantly associated with AR in the
pediatric dataset analyzed at Stanford and cross-validated in the
National Institutes of Health (NIH) SNSO1 randomized multi-
center trial [13]. An additional 14 genes (ABTB1, ANK1,
CEACAM4, CHST11, EPOR, IL2RB, MAP2K3, NFE2,
PCTP, PSMB9, RUNX3, SLC25A37, STAT3, YPEL3) were
selected from our initial blood microarray discovery performed
across three different microarray platforms [2] for having
significant differential expression in AR (significance analysis of
microarray false discovery rate ,5%). As our previous studies in
AR have consistently indicated that the AR gene signature in
blood is enriched in infiltrated leukocytes, particularly trafficking
monocytes, we further included in the 43-rejection-gene set genes
with enrichment in trafficking monocytes (C1orf38, GBP1,
GBP2, LYST, RARA, RXRA, TNFRSF1A); natural killer cells,
T lymphocytes, and dendritic cells (PFN1, ADAM8, RHEB,
GZMK); and endothelial cells (MMP1); significant enrichment was
determined as .3-fold increase above the mean expression in all
cells (using the GSE1133 dataset). Remaining genes were selected
based on other studies by our group on renal transplant AR (IL7,
IL7R, FOXP3, GZB; [1]) and in AR across organs (CXCL10,
ISG20, INPP5D; [3]). Four different housekeeping genes were
selected (18S, B2M, GAPDH, ACTB).
Selection of 17 genes for kSORT in Fluidigm QPCR
data. First, we evaluated the differential expression of ten out of
43 genes, selecting the same ten genes (CFLAR, DUSP1,
IFNGR1, ITGAX, MAPK9, NAMPT, NKTR, PSEN1,
RNF130, RYBP) that have been validated as diagnostic for AR
in PB using standardized clinical trial sample collection and
processing protocols [2]. The validation of the excellent discrim-
inatory potential of these genes for biopsy-confirmed AR was
conducted in a multicenter, US, randomized prospective clinical
trial (SNSO1), supported by the NIH National Institute of Allergy
and Infectious Diseases, in which a minimum set of different
combinations of five of the ten genes were sufficient to detect AR
in the graft [2,5,13]. These same ten genes were evaluated for their
ability to classify AR in a cohort of AR samples collected only from
adult renal transplant recipients (AART143), allowing for inclu-
sion of samples not collected under the same strict protocol
guidelines as used in the pediatric study [2]. To improve the
diagnostic accuracy for AR in the 143 adult samples, various
statistical modeling methods were used to include an additional
seven genes (CEACAM4, EPOR, GZMK, RARA, RHEB,
RXRA, SLC25A37), which improved the accuracy of the gene
panel for discriminating AR from No-AR samples, for a final
selection of 17 genes. These 17 genes were then validated for their
discriminatory performance in an independent cohort of both
adult and pediatric biopsy-matched blood samples (AART124)
collected by non-standardized non-clinical-trial methods as well as
by standardized clinical trial methods. The statistical methods used
for selection of the 17 genes included t-test statistics with the
Bonferroni post-correction or the q-value method to control the
false discovery rate (for differential gene expression analysis
between AR and No-AR); penalized logistic regression with the
lasso and elastic net regularization paths (to define genes with the
highest predictive power for AR) [20,21]; regularization paths for
generalized linear models via coordinate descent for estimations
for penalized logistic regression, available through the R package
glmnet [20]; and partial least squares discriminant analysis (plsDA)
(for gene selection with discriminant analyses and equal prior
probability for classification) [22], available through Partek
Genomics Suite version 6.6. For each bootstrap a nested cross-
validation loop estimated the best value for lambda according to
the deviance. The alpha parameter of the elastic net was fixed at
0.95 [20]. We counted the number of times each gene was selected
by the elastic net over 100 bootstraps and subsequently ranked the
genes by number of non-zero coefficients. We chose glmnet and
plsDA as they are particularly suitable statistical methods for
analysis of datasets with sparse numbers of observations and
correlated variables, and provide accurate class estimates for the
regression coefficients for selected genes and probability estimates
for each sample. Multivariate analyses were performed in SPSS
version 22 (SPSS Statistics, IBM, Chicago, IL) using linear
regression to test the influence of age, sample collection site, sample
source, and time post-transplant on the performance of kSORT
with a level of significance set to p#0.05. Receiver operating
characteristic (ROC) curves were generated in GraphPadPrism
vversion 5 (GraphPad, La Jolla, CA). For comparison of the areas
under the different ROC curves, the method by Hanley andMcNeil
was applied with a threshold for significance set at p#0.05 [23].
kSORT and kSAS development on ABI Viia7 data for
prospective analysis of acute rejection. Given the underlying
heterogeneity of the AART study samples, due to differences in
sample handling and co-morbidities in the adult population versus
the pediatric cohort, and to avoid the step of initial data
normalization [24], a new correlation-based algorithm named kSAS
was developed to allow for robust and easier classification of AR.
kSAS was developed to apply fixed AR and No-ARQPCR reference
profiles across the 17-gene panel to allow for accurate prospective
prediction of samples independent of input sample number, and thus
kSAS is feasible for translation to a routine clinical assay. kSAS uses
kSORT Assay to Detect Risk of Acute Rejection
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QPCR dCT or ddCT values generated from two reference QPCR
profiles (one for known AR and one for known No-AR), derived from
the mean gene expression signature (centroid) obtained frommultiple
AR or No-AR samples. When a given sample gene expression profile
is analyzed in kSAS, its expression is correlated to the reference
profiles for one or more developed gene sets (models). In the Fluidigm
dataset, kSAS was used to identify a single model composed of 14 of
the 17 genes. For the ABI analyses, multiple equivalent top-
performing gene sets (n=13) were discovered from the analysis of
samples from two collection sites (UCSF and UPMC) by randomly
selecting and testing the performance of all possible permutations of
different-sized gene sets of the 17 genes. Prior to discovery and testing
of the ABI samples in the AART100 dataset, reference centroids were
developed for different protocols (sample collection/processing
methods). All ABI samples were evaluated against this database of
reference centroids, with results reported for the centroid pair (AR
and No-AR) with the greatest correlation to the evaluated sample
(independent of collection methods). Classification of a sample as AR,
No-AR, or indeterminate was derived by computing the Pearson
correlation coefficients for all sample–centroid comparisons, assigning
a score of 1 to samples with a greater correlation to an AR centroid
and a score of 21 to samples with a greater correlation to a No-AR
centroid. A kSAS aggregated AR risk score (213 to 13) was then
determined by summing the scores for all evaluated gene models.
Indeterminate samples were defined as those with a score less than 9
and greater than29, based on evaluation of sample classification. All
gene models are provided in Table S1.
Results
Selection of 17 genes (kSORT) for Acute Rejection
Classification and Prediction
Initial evaluation of our previous ten-gene panel [2], which was
highly predictive of pediatric AR in the prospective SNS01 clinical
Figure 2. Training of a 17-gene model (kSORT) for acute rejection classification in 143 adult samples from real-life settings. 17 genes
were used to classify 143 adult blood samples from four different sites into AR and No-AR by plsDA (threshold for AR prediction H was set at
H= 50%). (A) AUC for AR in the training set was 0.94 (95% CI 0.91–0.98). (B) Predicted probabilities of AR were significantly higher in AR samples
versus No-AR samples for each collection site and did not reach the threshold for AR prediction in the No-AR samples (predicted probability threshold
H; H$50%). Mean predicted probabilities for AR were 98.6%, 75.9%, 86.8%, and 77.2% for CPMC, Emory, UPMC, and UCLA, respectively. Mean
predicted probabilities for No-AR were 13.7%, 19.4%, 11.3%, and 12.8% for CPMC, Emory, UPMC, and UCLA, respectively. Graphs show mean
predicted AR probabilities in percent plus standard error of mean; p-values were calculated by two-sided Student’s t test with Welch correction in
case of unequal variances.
doi:10.1371/journal.pmed.1001759.g002
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trial, was conducted in the AART143 training set of adult
samples (collected by non-standardized non-clinical-trial proto-
cols). Logistic regression modeling for these ten genes (DUSP1,
CFLAR, ITGAX, NAMPT, MAPK9, RNF130, IFNGR1,
PSEN1, RYBP, NKTR) correctly predicted 87.4% of the
samples (specificity of 93.8% [95% CI 86.89%–97.67%],
sensitivity of 74.50% [95% CI 59.65%–86.06%]), with an area
under the ROC curve (AUC) of 0.86 (95% CI 0.79–0.93)
(Figure S2). Out of the 43 genes tested, 31 genes were
differentially expressed in AR in adult renal transplant
recipients, and eight of these 31 differentially expressed genes
(q-value#0.05) were part of the original ten genes analyzed [2].
In the AART143 dataset, consisting of adult samples only, a
subset of 15 of the 43 genes (CEACAM4, CXCL10, GZB,
IL2RB, RARA, RHEB, SLC25A37, C1orf38, EPOR, GZMK,
ABTB1, NFE2, FOXP3, MMP1, MAP2K3) correctly classified
91.6% of the AR and No-AR samples (elastic net classification
with nested cross-validation) with a sensitivity of 85.9% and a
specificity of 94.2%. However, this approach was unsuccessful in
identification of AR in a purely pediatric data subset of the SNSO1
clinical trial [2,5,13], as only four of the 15 genes were selected
(EPOR, GZB, NFE2, SLC25A37). To maintain the integrity of the
assay to discriminate AR irrespective of recipient age, we retained
the original panel of ten genes [2] (DUSP1, CFLAR, ITGAX,
NAMPT, MAPK9, RNF130, IFNGR1, PSEN1, RYBP, NKTR).
The inclusion of seven additional genes (SLC25A37, CEACAM4,
RARA, RXRA, EPOR, GZMK, RHEB) optimized the perfor-
mance of the gene set for discriminating AR in both adult and
pediatric samples. These seven genes were identified by differential
expression analyses for AR versus No-AR in both AART143 (adult
samples only) and AART124 (adult and pediatric samples)
(q-value#5%: CEACAM4, RARA, RXRA, SLC25A37) and/or
selected by the elastic net (RHEB, EPOR, GZMK, CEACAM4,
RARA, SLC25A37) in the training set of AART143 samples. All 17
genes were selected (plsDA with equal prior probability) as the best
gene set for discriminating AR in samples from adult patients
(enrolled from four different US centers). The 17 genes predicted 39
of 47 AR samples correctly as AR, and 87 of 96 No-AR samples
correctly as No-AR, resulting in a sensitivity of 82.98% (95% CI
69.19%–92.35%) and specificity of 90.63% (95% CI 82.95%–
95.62%), with a calculated AUC of 0.94 (95% CI 0.91–0.98;
p,0.001) (Figure 2A; Table 2), which was significantly increased
compared to the AUC for the pediatric ten genes alone (one-sided
p=0.027, two-sided p=0.054 [23]). Mean predicted AR probabil-
ities were significantly different for AR versus No-AR in samples
from each of the four individual centers included in the AART143
dataset (CPMC: AR, 98.60%60.01; No-AR, 13.70%60.24; p,
0.001; Emory: AR, 76.00%60.38; No-AR, 19.4%60.3; p=0.002;
UPMC: AR, 86.80%60.19; No-AR, 11.60%60.21; p,0.001;
UCLA: AR, 77.20%60.35; No-AR, 11.40%60.16; p,0.001)
(Figure 2B). A flow diagram for the gene selection is provided in
Figure S2.
Independent Validation of the 17 Genes (kSORT) in a Test
Set of 124 Adult and Pediatric Recipients
To independently validate the 17-gene plsDA model devel-
oped in the AART143 samples (Fluidigm QPCR), we tested its
performance in a combined adult (n= 59) and pediatric (n= 65)
set of 124 independent samples (AART124). In the AART124
cohort, the 17-gene plsDA model predicted 21 of 23 AR samples
correctly as AR, and 100 of 101 No-AR samples correctly as No-
AR (Figure 3A; Table 2), including four patients with BKV
nephritis, yielding an assay sensitivity of 91.30% (95% CI
71.96%–98.93%) and specificity of 99.01% (95% CI 94.61%–
99.97%). One of the two misclassified AR samples had severe
chronic damage (interstitial fibrosis/tubular atrophy grade III),
with .33% global obsolescence in the biopsy sample at time of
rejection. As seen in the training set (AART143), mean predicted
probabilities of AR were also significantly different between the
AR (80.55%60.30) and No-AR (9.20%60.13) samples (p,
0.001; Figure 3B) in this validation set (AART124). Mean
predicted probabilities of AR in the BKV group were low, at
12.76%. ROC analyses in the 124 samples resulted in an AUC of
0.95 (95% CI 0.88–1.00) (Figure 3C). Two patients in the
AART124 cohort had an independent sample analyzed as part of
the AART143 cohort.
Equal Performance of kSORT in Samples from Four
Different Sample Collection Sites
To evaluate the performance of the 17-gene plsDA model at
each adult transplant center, we calculated AUCs for predictions
at Emory (n=42), UPMC (n=81), UCLA (n=44), and CPMC
(n=35) from AART143 and AART124. The performance of the
assay was equivalent at each transplant center ([23]; p.0.05), with
individual AUCs.0.8 at all four centers (Figure S3).
Table 2. Performance of kSORT in the AART143, AART124, and AART100 cohorts.
Statistics kSORT Predictions
AART143 (Training Set) AART124 (Validation Set) AART100 (Cross-Validation Set)
AR No-AR AR No-AR AR No-AR
Real Results
AR 39 8 21 2 36 3
No-AR 9 87 1 100 3 43
Sensitivity (95% CI) 82.98% (69.19%–92.35%) 91.30% (71.96%–98.93%) 92.31% (79.13%–98.38%)
Specificity (95% CI) 90.63% (82.95%–95.62%) 99.01% (94.61%–99.97%) 93.48% (82.1%–98.63%)
PPV (95% CI) 81.25% (68.06%–89.81%) 95.46% (78.20%–99.19%) 93.21% (79.68%–97.35%)
NPV (95% CI) 91.58% (84.25%–95.67%) 98.04% (93.13%–99.46%) 93.48% (82.45%–97.76)
AUC (95% CI) 0.94 (0.91–0.98) 0.95 (0.88–1.00) 0.92* (0.86–0.98)
*AUC was calculated based on kSORT scores for n= 100 patients including high risk for AR (n= 39), low risk for AR (n= 46), and indeterminate (n=15).
NPV, negative predictive value.
doi:10.1371/journal.pmed.1001759.t002
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Equal Detection of Antibody-Mediated and
Cell-Mediated Acute Rejection
Most of the AR samples analyzed on the Fluidigm platform
showed a mixed setting of some cellular and humoral rejection or
associated chronic changes. No difference in AR prediction scores
between 19 patients with clear antibody-mediated rejection
(ABMR) only (C4d+ biopsy staining, DSA+) and 51 patients with
clear cell-mediated rejection (TCMR) (C4d2 and DSA2, and
Banff t and i scores .1) was observed when assessed by the plsDA
17-gene model (p=0.99 for TCMR versus ABMR; TCMR
mean= 80.84%64.40; ABMR mean=80.75%66.60; Figure S4).
AR Prediction Is Independent of Time Post-
Transplantation and Recipient and Donor Age
Multivariate analyses in the AART143, AART124, and
AART100 cohorts evaluated the independence of kSORT
performance from time post-transplantation and recipient and
donor age. By linear regression, none of the tested variables except
for the predicted probability of AR (kSORT score) significantly
influenced the outcome for AR versus No-AR (p=0.009). We
additionally evaluated the performance of kSORT individually in
the AR and in the No-AR groups for time post-transplantation
categorized into 0–6 mo, 6 mo–1 y, and .1 y post-transplanta-
tion; comparing the kSORT scores using a one-way ANOVA
model with Tukey’s post-test for multiple comparisons, p-values in
each group did not reach significance (AR, p=0.22; No-AR,
p=0.60). Post-test for linear trend analysis in both the AR and
No-AR groups confirmed no significant association with time post-
transplantation (AR, p=0.10; No-AR, 0.36) (Figure S4).
Prediction of Biopsy-Confirmed Acute Rejection Prior to
Clinical Graft Dysfunction
To evaluate the predictive nature of the 17-gene plsDA model,
191 blood samples (AART191; prospective validation) drawn
either before (0.2–6.8 mo, n=65) or after (0.2–7 mo; n=52) a
biopsy-matched AR episode (n=74) were analyzed. Out of the
patients with blood samples 0–3 mo prior to the AR biopsy
(n=35), at time of stable graft function, 62.9% (22 out of 35
samples) had very high AR prediction scores (96.4%60.8)
(Figure 4; Table 3), significantly greater than scores in patients
with stable graft function and no AR on follow-up (19.4%60.3;
p,0.001). Of the patients with blood samples drawn 0–3 mo after
AR treatment (n=31), 51.6% (16 out of 31) still had elevated
predicted AR scores (86.00%60.17); the remaining 15 samples
showed AR scores below the threshold h for AR (h=50%;
6.59%60.13%) at 0–3 mo after AR treatment. As serum
creatinine levels in patients with elevated AR prediction scores
were 2.0460.40 mg/dl compared to creatinine levels of
Figure 3. Validation of kSORT in 124 independent samples across different ages and settings. (A) Independent validation of kSORT in
124 adult and pediatric AR and No-AR blood samples using the fixed plsDA model on the Fluidigm platform. 22 out of 23 AR samples were correctly
classified as AR (red bars), and 100 out of 101 No-AR samples were correctly classified as No-AR (green bars). Shown are individual predicted AR
probabilities (percent) grouped by patient age (adult, $20 y; pediatric, ,20 y) and phenotype. (B) predicted AR probabilities were significantly
higher in the AR (80.6%) versus No-AR (9.2%) samples (p,0.001) included in the AART124 group (shown are mean predicted AR probabilities in
percent with standard error of mean; two-sided Student’s t test with Welch correction was applied to calculate p-values). (C) ROC analyses
demonstrated high sensitivity and specificity for AR classification by the 17 genes.
doi:10.1371/journal.pmed.1001759.g003
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1.860.4 mg/dl in patients with decreased AR prediction scores,
the latter likely represented patients who responded to AR
treatment (Figure 4).
The Biological Basis of the 17 Genes
When evaluated in the context of experimentally predicted
interactions, more than half of the 17 genes in the plsDA model
were directly or indirectly associated with each other by common
molecular pathways (Figure S5), particularly regulation of
apoptosis, immune phenotype, and cell surface. In addition to
the ten genes previously evaluated as peripheral biomarkers for
pediatric AR, and known to be mostly expressed in PB cells of the
monocyte lineage [2], six of the additional seven peripheral AR
genes [25] were also expressed by activated monocytes (RXRA,
RARA, CEACAM4), endothelial cells (EPOR, SLC25A37), and T
cells (GZMK) in the peripheral circulation. Eleven of the 17 genes
played a common role in cell death and the cell survival network
(Fisher’s exact test, p,0.05; Ingenuity Pathway Analysis, [Qiagen,
Valencia, CA]; Figure S5).
Locking the 17-Gene kSORT Assay on the ABI Viia7 QPCR
Platform with kSAS, a Customized Analysis Suite
Having established the performance of the kSORT plsDA
model for detection and prediction of biopsy-confirmed AR in
pediatric and adult patients, the final kSORT assay was developed
on the ABI platform (ABI Viia7). To mitigate the data
normalization required to control for batch effect and sample
handling differences, we developed a new algorithm called kSAS
(Figure 5A) to classify samples using multiple covariate-impacted
reference sets, based on expression correlation (Pearson) of an
individual sample to each reference profile of AR and No-AR.
Rather than relying on a single gene set, this method creates and
uses multiple gene subsets (models), each of which is then
correlated to a reference AR or No-AR expression profile for a
given sample to provide a combined model score for each
reference. Samples with multiple disagreeing model predictions
(n.2) are considered indeterminate and thus cannot be confi-
dently assigned as AR or No-AR. The kSORT kSAS assay was
developed and cross-validated in 100 independent adult and
pediatric samples collected from 44 patients with AR and 56
patients without AR (Figure 5A).
Evaluation of kSAS performance in the Fluidigm
dataset. To develop the kSAS algorithm, we utilized the
Fluidigm QPCR dataset of the AART143 cohort and split the
samples into a training set of n=95 and a test set of n=48 by
random selection. From the 17 AR genes evaluated, kSAS
identified a single gene set model composed of 14 genes
(CEACAM4, CFLAR, DUSP1, EPOR, IFNGR1, NAMPT,
NKTR, PSEN1, RARA, RHEB, RNF130, RXRA, RYBP,
Figure 4. Evaluation of kSORT to predict acute rejection in 191 serially collected samples. 191 blood samples serially collected within
6 mo before (pre) or after (post) biopsy-confirmed AR were evaluated by kSORT. Frequencies of samples predicted as AR (red) or predicted as No-AR
(green) were compared between sample collection time points (.3 mo prior to AR biopsy, n=30; 0–3 mo prior to AR biopsy, n=35; at AR biopsy, n=74;
0–3 mo after AR biopsy, n=31; .3 mo after AR biopsy, n=21; and at No-AR/stable time points, n=216). 62.86% of samples collected 0–3 mo
(1.1560.90 mo) prior to the AR biopsy had high probabilities for AR predicted by kSORT (96.3660.08). High probabilities for AR persisted in 51.6% of
samples collected 0–3 mo post-AR (94.60%60.14); in comparison, 83.8% of the No-AR samples were always predicted as No-AR (8.20%60.12). Mean AR
scores were significantly different between pre-AR samples (0–3 mo) and No-AR/stable samples, as well as between AR samples and No-AR/stable
samples.
doi:10.1371/journal.pmed.1001759.g004
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Table 3. kSORT evaluation in AART191 for AR prediction.
Time from Rejection*
Percent Samples
Predicted as AR Predicted AR Probability**
Percent Samples
Predicted as No-AR Predicted AR Probability**
Pre .3 mo 26.3865.20 36.67% 95.37%60.10 63.33% 13.44%60.20
Pre 0–3 mo 21.1560.90 62.86% 96.36%60.08 37.14% 11.71%60.20
AR 83.78% 93.20%60.10 16.22% 26.36%60.20
Post 0–3 mo 1.2560.80 51.61% 85.96%60.20 48.39% 6.59%60.10
Post .3 mo 5.5762.70 42.86% 94.63%60.10 57.14% 1.48%60.03
No-AR 16.20% 80.30%60.20 83.80% 7.48%60.10
*Mean time from rejection in months 6 standard deviation.
**Mean predicted probability of AR 6 standard deviation.
doi:10.1371/journal.pmed.1001759.t003
Figure 5. Development of kSAS and the kSORT assay. kSAS was developed to provide individual sample AR risk scores and AR risk categories.
(A) Expression values of the 17-gene kSORT model in unknown samples were correlated to corresponding AR and No-AR reference values (centroids)
by Pearson correlation. (B) For kSORT assay development, QPCR data from 100 samples were divided into training (n=32) and independent validation
sets (n=68). (C) 13 12-gene models from the 17-gene kSORT model generated numerically aggregated AR risk scores for each sample and
categorized them into three groups: high risk for AR (aggregated AR risk score $9), low risk for AR (aggregated AR risk score #29), and
indeterminate (aggregated AR risk score ,9 and .29) category.
doi:10.1371/journal.pmed.1001759.g005
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SLC25A37) representing a combination of eight of the ten genes
from the Li et al. study [2] and six of the seven genes from the new
selection.
Locking the kSAS score in the ABI dataset. To account for
possible sample-protocol-associated covariates, mean gene expres-
sion measurements (centroids) were calculated from known AR
and known No-AR samples for the major experimental covariates
(sample collection/processing methods) to create a panel of
possible reference AR and No-AR profiles. For each evaluated
sample, kSAS automatically selects the most correlated reference
set for downstream classification. In contrast to other classification
algorithms, kSAS does not apply fixed mathematical coefficients,
and thus its output is not affected by differences in RNA
preparation and handling variances, which can affect QPCR data
ranges. Blood samples (n=32, UCSF and UPMC) confirmed as
AR (n=16) or No-AR (n=16) were evaluated by kSAS and tested
for the performance of over 130,000 different possible gene
combinations (3–17 genes per model). This analysis yielded 13
different 12-gene combinations utilizing a total of 15 of the 17
genes (CEACAM4, CFLAR, DUSP1, EPOR, GZMK, ITGAX,
MAPK9, NAMPT, NKTR, PSEN1, RARA, RHEB, RXRA,
RYBP, SLC25A37), with seven core genes present in all 13 12-
gene combinations (CEACAM4, CFLAR, EPOR, GZMK,
NKTR, PSEN1, SLC25A37) (Table S1). As our multiple model
approach provided distinct scores for each gene set, we evaluated
the combined ability of these models to provide a single confidence
score for each patient that is not based on a single gene model but
includes all 13 12-gene models. This aggregated AR risk analysis
produced a numerical AR risk score for each patient (213 to 13),
by simply subtracting the number of times a patient was predicted
as No-AR by the 13 12-gene models from the number of times the
same patient was predicted as AR.
Validation of kSAS in independent samples from adult
and pediatric transplant recipients. To assess the perfor-
mance of the fixed kSAS algorithm utilizing the 13 12-gene
models, we calculated aggregated AR risk scores for the combined
dataset of 100 AR and No-AR samples (26 AR, 42 No-AR;
AART100). The large majority of samples were classified as AR or
No-AR with all kSAS gene models in agreement (81 out of 100).
Given the large agreement in model predictions, to minimize false
positive AR predictions, if three or more disagreeing calls (,1/4 of
the models) occurred, the sample was classified as indeterminate,
otherwise the sample was predicted to be high risk for AR ($11
AR calls; combined score $9), or low risk for AR ($11 No-AR
calls; combined score #29) (Figure 5). Among patients predicted
as high risk, 92.3% were classified correctly as AR (36 out of 39);
among patients predicted as low risk for AR, 93.5% (43 out of 46)
were classified correctly as No-AR based on the biopsy reading
(Table 2), resulting in a sensitivity of 92.31% (95% CI 79.13%–
98.38%) and specificity of 93.48% (95% CI 82.10%–98.63%). The
remaining patients (n=15) were predicted as indeterminate
(Figure 6A). The combined kSORT scores in the AR samples
(10.267.2; n=42) were significantly higher than those in the No-
AR samples (28.4%68.2; n=58) by two-sided Student’s t test,
with p,0.001 (Figure 6B). The AUC for the combined kSORT
scores from all 100 samples was 0.918 (95% CI 0.856–0.981)
(Figure 6C).
Discussion
Clinical availability of molecular tests for accurate disease
diagnosis and patient stratification for treatment regimens is a
pressing issue in medicine. Molecular classification of acute
transplant rejection independent of the invasive biopsy procedure
is a much needed clinical assay [10,26]. Recent scientific research
has highlighted the deficiencies of using histology alone as a means
for detecting AR, with its inherent problems of sampling, read
variability, and the inability to use the biopsy for serial monitoring
and AR prediction [7,8].
In the present study we developed a simple yet sensitive and
specific noninvasive QPCR test, kSORT, together with a novel
algorithm, kSAS, for the detection and prediction of acute renal
allograft rejection from a PB sample, irrespective of the rejection
grade or pathological diagnosis of antibody- or cell-mediated
rejection. kSORT accurately indicated the risk and prevalence of
acute renal rejection in 558 PB samples from 436 adult and
pediatric renal transplant patients based on the expression of 17
genes (final AUC=0.92, 95% CI 0.86–0.98). The kSORT assay
performance was independent of age, time post- transplantation,
transplant-specific patient management, and sample processing.
The kSAS algorithm, which correlates the expression of an
individual patient sample to multiple gene AR and No-AR
reference profiles across multiple overlapping gene models, was
successful at classifying samples with known sample handling
variables.
The approach we applied here combined our previous findings
in pediatric transplant patients in a clinical trial setting with a
novel discovery in adult and pediatric transplant patients from a
‘‘real-life’’ setting. We advanced our recent transcriptional panel of
ten genes previously shown to be differentially regulated in blood
from patients with AR in different solid organs (the kidney [2,26]
and the heart [4,27]). This initial AR panel assay was developed in
a cohort of pediatric-only renal transplant patients with low risk of
AR (pre-transplant panel reactive antibody level ,20%; n=279;
ages 1–21 y) as part of an NIH-funded randomized trial in 12 US
centers [26], with stringent control of the standard operating
procedure for patient care and blood sample processing. We
performed additional QPCR in PB samples collected in the
present AART study, which represents a real-life heterogeneous
transplant cohort of 436 adult and pediatric patients from eight
independent transplant centers, where samples were collected
irrespective of the patients’ immunologic risk, immunosuppression,
and co-morbidities, and where different blood RNA sampling
methodologies were applied. This approach allowed for the
development of an assay for which performance is robust against
clinical and experimental confounders—important assets of
kSORT and the kSAS algorithm, as multiple studies have shown
that such confounders are associated with wide variability in the
quality and reproducibility of gene expression data [28–31] and
are likely to confound the interpretability of test results.
Another strength of the kSORT assay is its high positive
predictive value (PPV) (93.21%) for detecting AR in a PB sample.
The only PB diagnostic test that is currently available for detecting
transplant rejection in transplant patients [32] detects the absence
of moderate/severe acute cellular cardiac rejection (ISHLT 3A),
but provides low sensitivity for detection of the presence of AR
(PPV=6.8%) [32]. Similarly, a blood gene expression test for
assessing obstructive coronary artery disease (CorusCad, Cardi-
oDx, Palo Alto, CA) yielded a PPV of 46% in a multicenter
validation study [33]. In addition to the high sensitivity of kSORT
to detect AR at the point of rejection (as diagnosed by the current
gold standard), kSORT was able to identify subclinical AR in 12
out of 16 subclinical rejections that were included in the
AART100 cohort and predicted clinical AR in .60% of samples
collected up to 3 mo prior to graft dysfunction and histological
AR—an important ability for a rejection test, as subclinical and
clinical AR are precursors of chronic rejection and graft loss [5].
Although current immune-monitoring tools for assessing the
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adaptive alloimmune response have shown their usefulness for
predicting the potential risk of AR [34,35], detection of donor-
specific antibodies or memory-effector T cells does not necessarily
translate to ongoing immune-mediated allograft damage, and
these effector mechanisms may not always be detected prior to or
at the time of biopsy-proven AR. Furthermore, most centers
currently do not perform protocol biopsies as a means to detect
subclinical AR, and thus subclinical cases remain largely
undetected. The kSORT assay is promising for routine noninva-
sive post-transplant monitoring to predict AR and limit graft
damage with timely intervention. The high specificity of the
kSORT assay suggests its potential value to be additionally used as
a negative predictor of rejection in the graft.
A constraint of the kSORT assay in its current assay design is its
inability to discriminate between TCMR and ABMR in our study.
Two potential explanations could account for this observation; on
the one hand, a likely link lies in a common finding of monocyte
activation in both types of AR, as the kSORT genes were highly
enriched in monocytes. Indeed, monocytes are critical cells that
can directly mediate the injury of tubulitis in TCMR in the
allograft; additional evidence exists that donor-specific HLA class I
antibodies in ABMR activate endothelial cells, which in turn can
recruit and activate monocytes and leukocytes, increasing graft
inflammation [36]. On the other hand, the common kSORT gene
expression in both cellular and humoral rejections may represent
hierarchical architecture of the adaptive immune response that
takes place during the rejection process, rather than clustering with
any specific effector mechanism responsible for each type of
allograft rejection. In fact, some genes were also highly expressed
in CD4+ and CD8+ T cells, whereas some others were highly up-
regulated in B cells or dendritic cells, thus suggesting the close
interplay between both main effector mechanisms of the adaptive
immune response during allograft rejection [37]. Recent studies
where gene expression analyses allowed for discrimination of
ABMR and TCMR were based on transcriptional studies of the
rejecting biopsy tissue [38], most valuable to better understand
underlying molecular mechanisms that may differentiate ABMR
and TCMR based on injury localization in specific compartments
of the kidney biopsy (endothelial cells in ABMR versus tubular
cells in TCMR) or the specific major effector mechanisms of injury
Figure 6. Performance of the kSORT assay. (A) kSORT score and classification category were calculated for each sample: the kSORT assay
correctly classified 36 out of 39 AR samples as high risk for AR (red bars, 92.3%; risk score $9) and 43 out of 46 No-AR samples as low risk for AR
(green bars, 93.5%, risk score#29) across four different sample collection sites, and adult ($20 y) versus pediatric (,20 y) recipient age groups, with
samples collected in clinical trial and non-clinical-trial settings; remaining 15 samples classified as indeterminate risk for AR (grey bars; risk score ,9
and.29). (B) Mean aggregated kSORT scores (error bars give standard error of mean) were significantly higher in all true AR samples (10.267.2) than
in all true No-AR samples (28.4%68.2) in the AART100 cohort by two-sided Student’s t test. (C) ROC analysis demonstrated high sensitivity and
specificity for the kSORT assay in the AART100 cohort.
doi:10.1371/journal.pmed.1001759.g006
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(natural killer cells in ABMR versus cytotoxic T cells in TCMR)
[2,4,39–42]. Of note, down-regulation of kSORT genes in patients
with other underlying inflammatory processes such as BKV
infection and non-allospecific nephritis suggests that despite being
a monocyte-driven transcriptional signature, kSORT illustrates
the activation of an allogeneic immune response.
Similar to our recent observation of a common rejection module
(CRM; n=11 genes) in tissue across heart, liver, lung, and kidney
allografts [3], the present study in blood also finds genomic
commonalities for the 17 genes across kidney [2] and heart [4] and
across pediatric [2] and adult [4] transplant recipients. The
combined learning in blood and tissue supports the postulation
that immune perturbation is global, synonymous across transplant
organs and unaffected by age, suggesting a common immunolog-
ical axis. This apparent commonality supports the future
evaluation of kSORT for patient monitoring beyond kidney
transplantation. Nevertheless, the CRM genes detected in tissue
do not overlap with our kSORT genes detected in blood, which is
not surprising as the predominant expression changes in the graft
reflect cellular infiltration and inflammation, and are likely
different from the signals of activated trafficking cells in the
periphery.
A limitation of our study is the currently unavoidable fact that
the reference for evaluation of our blood test performance is based
on histological readings, with their aforementioned shortcomings,
which serve as the current gold standard for detection of rejection.
Moreover, the lack of centralized histological information for all
biopsy samples might be considered as an additional constraint,
even though all tissue samples were evaluated following the
current gold standard Banff score classification for the description
of main allograft lesions [14]. Furthermore, kSORT needs to be
evaluated in a prospective clinical trial before its clinical efficacy
can be determined. To clinically evaluate the diagnostic and
predictive performance of kSORT, we have included patient
monitoring by kSORT in a prospective, randomized, double-
blinded clinical trial (Steroid Avoidance and Low-Dose CNI by
ATG-Induction in Renal Transplantation [SAILOR]; EU Clinical
Trials Register SUGBG-012011). The results of this trial will
further evaluate whether kSORT can be used as an objective and
quantitative measure for the risk of AR, and whether kSORT can
be used serially post-transplant to complement current clinical
practice guidelines for stratifying patient immune risk, medication
load, and requirement for biopsy.
In conclusion, in this report we present the validation of the
kSORT assay to detect risk of AR in renal transplant patients; the
kSORT assay has the potential to become a simple, robust, and
clinically applicable blood test.
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Editors’ Summary
Background. Throughout life, the kidneys filter waste
products (from the normal breakdown of tissues and food)
and excess water from the blood to make urine. If the
kidneys stop working for any reason, the rate at which the
blood is filtered decreases, and dangerous amounts of
creatinine and other waste products build up in the blood.
The kidneys can fail suddenly (acute kidney failure) because
of injury or poisoning, but usually failing kidneys stop
working gradually over many years (chronic kidney disease).
Chronic kidney disease is very common, especially in people
who have high blood pressure or diabetes and in elderly
people. In the UK, for example, about 20% of people aged
65–74 years have some degree of chronic kidney disease.
People whose kidneys fail completely (end-stage kidney
disease) need regular dialysis (hemodialysis, in which blood
is filtered by an external machine, or peritoneal dialysis,
which uses blood vessels in the abdominal lining to do the
work of the kidneys) or a renal transplant (the surgical
transfer of a healthy kidney from another person into the
patient’s body) to keep them alive.
Why Was This Study Done? Our immune system protects
us from pathogens (disease-causing organisms) by recog-
nizing specific molecules (antigens) on the invader’s surface
as foreign and initiating a sequence of events that kills the
invader. Unfortunately, the immune system sometimes
recognizes kidney transplants as foreign and triggers
transplant rejection. The chances of rejection can be
minimized by ‘‘matching’’ the antigens on the donated
kidney to those on the tissues of the kidney recipient and by
giving the recipient immunosuppressive drugs. However,
acute rejection (rejection during the first year after trans-
plantation) affects about 20% of kidney transplants. Acute
rejection needs to be detected quickly and treated with a
short course of more powerful immunosuppressants be-
cause it increases the risk of transplant failure. The current
‘‘gold standard’’ method for detecting acute rejection if the
level of creatinine in the patient’s blood begins to rise is to
surgically remove a small piece (biopsy) of the transplanted
kidney for analysis. However, other conditions can change
creatinine levels, acute rejection can occur without creatinine
levels changing (subclinical acute rejection), and biopsies are
invasive. Here, the researchers develop a noninvasive test for
acute kidney rejection called the Kidney Solid Organ
Response Test (kSORT) based on gene expression levels in
the blood.
What Did the Researchers Do and Find? For the
Assessment of Acute Rejection in Renal Transplantation
(AART) study, the researchers used an assay called quanti-
tative polymerase chain reaction (QPCR) to measure the
expression of 43 genes whose expression levels change
during acute kidney rejection in blood samples collected
from patients who had had a kidney transplant. Using a
training set of 143 samples and statistical analyses, the
researchers identified a 17-gene set (kSORT) that discrimi-
nated between patients with and without acute rejection
detected by kidney biopsy. The 17-gene set correctly
identified 39 of the samples taken from 47 patients with
acute rejection as being from patients with acute rejection,
and 87 of 96 samples from patients without acute rejection
as being from patients without acute rejection. The
researchers validated the gene set using 124 independent
samples. Then, using 191 serial samples, they showed that
the gene set was able to predict acute rejection up to three
months before detection by biopsy. Finally, the researchers
used 100 blood samples to develop an algorithm (a step-
wise calculation) to classify patients as being at high or low
risk of acute rejection.
What Do These Findings Mean? These findings describe
the early development of a noninvasive tool (kSORT) that
might, eventually, help clinicians identify patients at risk of
acute rejection after kidney transplantation. kSORT needs to
be tested in more patients before being used clinically,
however, to validate its predictive ability, particularly given
that the current gold standard test against which it was
compared (biopsy) is far from perfect. An additional
limitation of kSORT is that it did not discriminate between
cell-mediated and antibody-mediated immune rejection.
These two types of immune rejection are treated in different
ways, so clinicians ideally need a test for acute rejection that
indicates which form of immune rejection is involved. The
authors are conducting a follow-up study to help determine
whether kSORT can be used in clinical practice to identify
acute rejection and to identify which patients are at greatest
risk of transplant rejection and may require biopsy.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001759.
N The US National Kidney and Urologic Diseases Information
Clearinghouse provides links to information about all
aspects of kidney disease; the US National Kidney Disease
Education Program provides resources to help improve the
understanding, detection, and management of kidney
disease (in English and Spanish)
N The UK National Health Service Choices website provides
information for patients on chronic kidney disease and
about kidney transplants, including some personal stories
N The US National Kidney Foundation, a not-for-profit
organization, provides information about chronic kidney
disease and about kidney transplantation (in English and
Spanish)
N The not-for-profit UK National Kidney Federation provides
support and information for patients with kidney disease
and for their carers, including information and personal
stories about kidney donation and transplantation
N World Kidney Day, a joint initiative between the Interna-
tional Society of Nephrology and the International
Federation of Kidney Foundations, aims to raise awareness
about kidneys and kidney disease
N MedlinePlus provides links to additional resources about
kidney diseases, kidney failure, and kidney transplantation;
the MedlinePlus encyclopedia has a page about transplant
rejection
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